Clinical trials: Prostate Cancer Stage
Hormone Refractory Prostate Cancer
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis…
- Trial name
- NCT00286091
- Testing
- Denosumab
- Volunteers
- 1,435 people
- Sponsor
- Amgen
Neoplasms
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist.
- Trial name
- NCT00487786
- Testing
- OGX-427, Docetaxel
- Where
- 3 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Achieve Life Sciences
Advanced Prostate Cancer
A Study of QLS2401 Injection in Participants With Advanced Prostate Cancer
This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, immunogenicity, and preliminary antitumor activity of QLS2401…
- Trial name
- NCT07869888
- Testing
- QLS2401
- Volunteers
- 252 people
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Prostatic Neoplasms
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the…
- Trial name
- NCT07082920
- Testing
- JNJ-78278343, JNJ-95298177, JNJ-87189401
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants…
- Trial name
- KEYLYNK-010 (NCT03834519)
- Testing
- Pembrolizumab, Olaparib, Abiraterone acetate
- Where
- 193 sites in United States, Argentina and 18 more
- Volunteers
- 793 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC)…
- Trial name
- NCT03148795
- Testing
- Talazoparib
- Where
- 120 sites in United States, Australia and 12 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Prostatic Neoplasms
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is…
- Trial name
- NCT07319871
- Testing
- Pasritamig, JNJ-86974680
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Janssen Research & Development, LLC
Hormone Refractory Prostate Cancer, Bone Metastases
BAY88-8223, Does Response Study in HRPC Patients
The purpose of this study is to evaluate the efficacy and safety of the investigational radioisotope Radium-223, Xofigo (Alpharadin), in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal…
- Trial name
- NCT00667199
- Testing
- Radium-223 dichloride (BAY88-8223)
- Volunteers
- 100 people
- Sponsor
- Bayer
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
A Phase I Trial of A-CAR032 in Participants With mCRPC
This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with…
- Trial name
- NCT07344311
- Testing
- dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection
- Where
- 4 sites in China
- Volunteers
- 27 people
- Sponsor
- Shanghai AbelZeta Ltd.
Prostate Cancer
Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
Docetaxel (Taxotere) is an approved chemotherapeutic drug for the treatment of androgen-independent prostate cancer. The aim of the study is to investigate whether addition of the investigational drug PI-88 will increase the…
- Trial name
- NCT00268593
- Testing
- PI-88, docetaxel, prednisone
- Where
- 8 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Progen Pharmaceuticals
Prostate Cancer
Trial of eRapa in Prostate Cancer Patients
This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic impact of encapsulated rapamycin in patients with low risk prostate cancer under active surveillance.
- Trial name
- NCT03618355
- Testing
- eRapa (encapsulated rapamycin)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rapamycin Holdings, Inc. dba Emtora Biosciences
Metastatic Breast Cancer, Metastatic Colon Cancer
Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Metastatic Colon Cancer, Metastatic Prostate Cancer
- Trial name
- NCT02655952
- Testing
- Foxy-5
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 17 people
- Sponsor
- WntResearch AB
Prostate Cancer Metastatic
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide…
- Trial name
- mCRPC (NCT03888612)
- Testing
- ARV-110
- Where
- 54 sites in United States
- Volunteers
- 248 people
- Sponsor
- Arvinas Inc.
Prostatic Neoplasm
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor…
- Trial name
- ODYSSEY (NCT00174863)
- Testing
- SR31747A
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 232 people
- Sponsor
- Sanofi
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostatic Cancer, Castration-Resistant
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- DaroAcT (NCT04157088)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Metastatic Castration-Resistant Prostate Cancer
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT02861573
- Testing
- Pembrolizumab 200 mg, Olaparib 400 mg, Docetaxel 75 mg/m^2
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostatic Neoplasms
Safety Study of TAK-700 in Subjects With Prostate Cancer.
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
- Trial name
- TAK-700 (NCT00569153)
- Testing
- TAK-700
- Where
- 19 sites in United States
- Volunteers
- 123 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hormone-refractory Prostate Cancer
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment.
- Trial name
- NCT05997615
- Testing
- VIR-5500, Androgen receptor signaling inhibitor (ARSI), Docetaxel
- Where
- 26 sites in United States, Australia and 2 more
- Volunteers
- 347 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer.
- Trial name
- PrTK03 (NCT01436968)
- Testing
- Aglatimagene besadenovec + valacyclovir
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 711 people
- Sponsor
- Candel Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.